Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia pneumonia: 10 years experience of single center
Conclusions: S. maltophilia is emerging as an important pathogen with increased risk of mortality. Empiric therapy should include agents active against S.maltophilia such as newer flouroquinolones and trimethoprim-sulfamethoxazole.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Havlucu, Y., Kızılırmak, D. Tags: Respiratory infections Source Type: research
More News: Bactrim | Cancer & Oncology | Chronic Obstructive Pulmonary | Cystic Fibrosis | Hematology | Intensive Care | Pneumonia | Renal Failure | Respiratory Medicine | Study | Sulfamethoxazole | Trimethoprim